• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Glaukos

edit

Glaukos Corporation is committed to transforming glaucoma therapy. To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management. Today, they are at the beginning with an innovative micro technology. In collaboration with their clinician partners, they are building technology towards a safer and more effective treatment for preserving vision in patients with primary open-angle glaucoma.

Recent Milestones

edit

• 
  Glaukos received $30M in Series F funding. (2/7/13)
  Posted 2/7/13 at 8:17pm via dowjones.com
• 
  Glaukos received $29.5M in Series E funding. (2/2/11)
  Posted 2/2/11 at 11:01pm via dowjones.com
• 
  Glaukos received $35M in Series D funding. (8/29/08)
  Posted 6/22/09 at 8:17pm via equityhelpdesk.com
• 
  Glaukos received $10M in Series A funding. (9/1/02)
  Posted 2/9/13 at 5:43am via privco.com
• 
  Glaukos added Paul Madera as Board Observer.
  Posted 4/19/11 at 7:06pm

Videos

Screenshots

edit

Above: Glaukos
Uploaded: 6/23/09

Sources

1. Glaukos Receives Series A Investment From Domain Associates, LLC, Versant Ventures, And Frazier Healthcare Ventures (privco.com) [edit]
2. Glaukos Adds $35 Million (equityhelpdesk.com) [edit]
3. Glaukos Sees $29.5M Series E Round For Tiny Eye Device (fis.dowjones.com) [edit]
4. Glaukos Spots $30M for Eyeball Stent, Doesn't Blink in Ivantis Rivalry (pevc.dowjones.com) [edit]